GH Research PLC (GHRS) Stock Analysis
Healthcare · Biotechnology · NasdaqGM
GH Research PLC (GHRS) posted $0 in revenue for fiscal 2025, with a net loss of $48.26M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on GH Research PLC
GH Research PLC has grown revenue from $0 to $0 over the last 4 fiscal years.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from GH Research PLC's SEC filings — descriptive, not advice. Ask the analyst your own question →
GH Research PLC revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-22.46M | $-35.59M | $-38.96M | $-48.26M |
| Net margin | — | — | — | — |
Source: GH Research PLC SEC filings (10-K).
GH Research PLC: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 19.2% over 3 years (52M → 62M) — existing holders' stakes are being diluted.
Explore 4 years of GH Research PLC financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track GHRS in your portfolio →
GH Research PLC financial history by metric
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
GH Research PLC — frequently asked questions
What is GH Research PLC's revenue?
GH Research PLC (GHRS) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is GH Research PLC profitable?
No — GHRS reported a net loss of $-48.26M in fiscal 2025.
What is GHRS's P/E ratio?
GH Research PLC trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does GH Research PLC have?
As of fiscal year 2025, GHRS carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is GH Research PLC's market cap?
GH Research PLC (GHRS) has a market capitalization of about $1.41B, based on the latest data in our nightly-refreshed cache.
When does GH Research PLC's fiscal year end?
GHRS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from GH Research PLC's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.